XML Sitemap

This is a XML Sitemap which is supposed to be processed by search engines which follow the XML Sitemap standard like Ask.com, Bing, Google and Yahoo.
It was generated using the WordPress content management system and the Google Sitemap Generator Plugin by Arne Brachhold.
You can find more information about XML sitemaps on sitemaps.org and Google's list of sitemap programs.

URLPriorityChange frequencyLast modified (GMT)
https://xconomy.com/san-diego/2020/01/31/arcutis-bio-raises-159m-in-upsized-ipo-to-test-skin-disease-drugs/60%Monthly2020-01-31 23:52
https://xconomy.com/national/2020/01/31/bio-roundup-mammoth-moves-black-diamonds-pop-ohanas-debut-more/60%Monthly2020-01-31 14:19
https://xconomy.com/boston/2020/01/30/moderna-adds-takedas-melanie-ivarsson-as-chief-development-officer/60%Monthly2020-01-31 13:55
https://xconomy.com/boston/2020/01/30/disc-medicine-adds-longtime-acceleron-pharma-exec-as-new-ceo/60%Monthly2020-01-31 13:57
https://xconomy.com/national/2020/01/30/bio-report-more-work-needed-to-improve-diversity-at-biotech-firms/60%Monthly2020-01-30 23:09
https://xconomy.com/san-francisco/2020/01/30/with-45m-mammoth-bio-expects-big-things-from-tiny-crispr-cas14/60%Monthly2020-01-30 20:02
https://xconomy.com/boston/2020/01/30/black-diamonds-upsized-ipo-raises-201m-to-advance-its-cancer-drug-rd/60%Monthly2020-01-30 16:49
https://xconomy.com/boston/2020/01/30/vizgen-launches-with-14m-to-market-new-subcellular-imaging-technique/60%Monthly2020-01-30 14:26
https://xconomy.com/new-york/2020/01/29/annovis-bio-gets-12m-in-ipo-to-target-trio-of-neurotoxic-proteins/60%Monthly2020-01-30 00:41
https://xconomy.com/boston/2020/01/29/anika-therapeutics-announces-passing-of-ceo-joseph-darling/60%Monthly2020-01-29 23:06
https://xconomy.com/boston/2020/01/29/decibel-therapeutics-exec-holtzman-retires-reid-named-acting-ceo/60%Monthly2020-01-29 20:27
https://xconomy.com/boston/2020/01/29/takedas-blanchfield-joins-lantheus-as-chief-commercial-officer/60%Monthly2020-01-29 21:21
https://xconomy.com/boston/2020/01/29/biofourmis-adds-jaydev-thakkar-milan-shah-to-c-suite/60%Monthly2020-01-29 20:10
https://xconomy.com/boston/2020/01/29/spring-bank-pharma-ends-hepatitis-b-work-after-death-in-clinical-trial/60%Monthly2020-01-29 17:46
https://xconomy.com/national/2020/01/29/agenda-and-speakers-announced-for-xcelerating-life-sciences-san-diego/60%Monthly2020-01-29 15:41
https://xconomy.com/boston/2020/01/29/decibel-therapeutics-strikes-a-balance-adding-regenerative-med-focus/60%Monthly2020-01-29 15:57
https://xconomy.com/san-diego/2020/01/28/histogen-timber-pharma-plan-reverse-mergers-to-join-public-markets/60%Monthly2020-01-29 04:25
https://xconomy.com/boston/2020/01/28/third-times-the-charm-as-acceleron-drug-shows-early-promise-in-pah/60%Monthly2020-01-28 23:16
https://xconomy.com/boulder-denver/2020/01/28/biointellisense-debuts-sticker-sensor-to-capture-patient-data-remotely/60%Monthly2020-01-29 04:29
https://xconomy.com/new-york/2020/01/28/passage-bio-appoints-deerfield-managements-bruce-goldsmith-as-ceo/60%Monthly2020-02-04 03:34
https://xconomy.com/national/2020/01/28/advanced-therapies-are-reshaping-biopharma-rd-kpmg-report/60%Monthly2020-01-28 13:55
https://xconomy.com/boston/2020/01/27/flagship-adds-fertility-focused-ohana-biosciences-to-biotech-family/60%Monthly2020-01-28 02:12
https://xconomy.com/boston/2020/01/27/quench-bio-springs-from-atlas-with-50m-for-a-new-take-on-inflammation/60%Monthly2020-01-28 05:13
https://xconomy.com/national/2020/01/27/life-sciences-ipos-target-collective-raise-of-more-than-600m-this-week/60%Monthly2020-01-27 16:00
https://xconomy.com/national/2020/01/27/allergan-offloads-two-drugs-to-secure-approval-of-merger-with-abbvie/60%Monthly2020-01-27 16:53
https://xconomy.com/boston/2020/01/24/beam-therapeutics-promotes-giuseppe-ciaramella-to-president/60%Monthly2020-01-24 19:54
https://xconomy.com/boston/2020/01/24/acceleron-pharma-exec-quisel-is-leaving-to-join-a-biotech-startup/60%Monthly2020-01-24 22:56
https://xconomy.com/national/2020/01/24/bio-roundup-coronavirus-concerns-sareptas-crl-eye-drug-okd-more/60%Monthly2020-01-24 15:17
https://xconomy.com/boston/2020/01/23/epizymes-soft-tissue-cancer-drug-granted-speedy-fda-approval/60%Monthly2020-01-24 01:19
https://xconomy.com/san-diego/2020/01/23/kura-oncology-chief-medical-officer-plans-to-step-down-next-month/60%Monthly2020-01-24 01:01
https://xconomy.com/boston/2020/01/23/poxel-picks-sigilons-moller-for-chief-scientific-officer-post/60%Monthly2020-01-23 20:50
https://xconomy.com/national/2020/01/23/krystal-biotech-names-genzymes-chien-chief-commercial-officer/60%Monthly2020-01-23 20:44
https://xconomy.com/national/2020/01/23/after-astrazeneca-osbourn-reflects-on-roles-at-cat-medimmune/60%Monthly2020-01-23 14:50
https://xconomy.com/boston/2020/01/22/fda-flags-risk-of-infection-kidney-damage-for-sarepta-duchenne-drugs/60%Monthly2020-01-23 00:32
https://xconomy.com/new-york/2020/01/22/healthcare-investment-trends-where-will-the-money-flow-in-2020/60%Monthly2020-01-22 17:54
https://xconomy.com/national/2020/01/22/horizon-gets-early-fda-ok-for-first-thyroid-eye-disease-treatment/60%Monthly2020-01-22 12:56
https://xconomy.com/new-york/2020/01/22/emendo-eyes-the-clinic-for-crispr-therapy-that-makes-single-gene-edits/60%Monthly2020-01-22 12:11
https://xconomy.com/san-diego/2020/01/22/ceos-of-womens-health-companies-fight-to-open-investment-floodgates/60%Monthly2020-01-22 14:21
https://xconomy.com/san-diego/2020/01/21/after-ending-cancer-drug-program-halozyme-predicts-profits-in-2020/60%Monthly2020-01-22 01:48
https://xconomy.com/boston/2020/01/21/of-science-and-sea-urchins-researchers-plumb-oceans-for-biological-insights/60%Monthly2020-01-21 13:30
https://xconomy.com/san-francisco/2020/01/17/revolution-medicines-maps-out-an-ipo-to-reach-cancers-frontiers/60%Monthly2020-01-18 04:45
https://xconomy.com/national/2020/01/17/bio-roundup-eqrxs-ambitions-nektar-no-vote-new-frazier-fund-more/60%Monthly2020-01-17 21:26
https://xconomy.com/raleigh-durham/2020/01/16/biocryst-pharma-promotes-charles-gayer-to-chief-commercial-officer/60%Monthly2020-01-16 23:21
https://xconomy.com/boston/2020/01/16/cancer-drug-developer-biontech-to-buy-neon-therapeutics-in-67m-deal/60%Monthly2020-01-16 21:17
https://xconomy.com/national/2020/01/16/adaptimmune-appoints-elliot-norry-chief-medical-officer/60%Monthly2020-01-16 15:15
https://xconomy.com/national/2020/01/16/event-announcement-xcelerating-life-sciences-san-diego/60%Monthly2020-01-16 15:29
https://xconomy.com/boston/2020/01/16/mayo-clinic-joins-60m-financing-for-biomedical-software-firm-nference-2/60%Monthly2020-01-16 14:02
https://xconomy.com/boston/2020/01/15/disarm-therapeutics-names-scott-holmes-chief-financial-officer/60%Monthly2020-01-16 00:22
https://xconomy.com/new-york/2020/01/15/emendo-biotherapeutics-nabs-61m-for-next-generation-crispr-rd/60%Monthly2020-01-22 12:17
https://xconomy.com/san-diego/2020/01/15/xcelerating-life-sciences-san-diego/60%Monthly2020-01-23 17:37
https://xconomy.com/national/2020/01/15/phage-therapy-firm-apt-lands-dod-contact-for-antibiotic-alternative/60%Monthly2020-01-15 15:21
https://xconomy.com/national/2020/01/14/fda-panel-votes-down-nektar-opioid-painkiller-asks-for-more-data/60%Monthly2020-01-15 14:07
https://xconomy.com/national/2020/01/14/pfizer-taps-insilico-medicine-to-use-ai-for-drug-target-discovery/60%Monthly2020-01-15 01:55
https://xconomy.com/new-york/2020/01/14/schrodinger-sets-course-for-ipo-to-support-growing-internal-pipeline/60%Monthly2020-01-14 16:27
https://xconomy.com/san-diego/2020/01/14/dare-bioscience-inks-deal-with-bayer-for-non-hormonal-contraceptive/60%Monthly2020-01-14 06:33
https://xconomy.com/national/2020/01/13/neogenomics-nabs-human-longevitys-oncology-division-for-37m/60%Monthly2020-01-14 06:41
https://xconomy.com/boston/2020/01/13/biogen-adds-another-neuro-drug-to-pipeline-in-deal-with-pfizer/60%Monthly2020-01-13 20:50
https://xconomy.com/national/2020/01/13/incyte-commits-900m-to-morphosys-for-rights-to-lymphoma-drug/60%Monthly2020-01-13 21:39
https://xconomy.com/boston/2020/01/13/generation-bio-pockets-110m-for-next-wave-of-gene-therapy-ipo-plans/60%Monthly2020-01-13 16:22
https://xconomy.com/national/2020/01/13/roche-pays-40m-to-use-amunixs-half-life-extension-tech/60%Monthly2020-01-13 13:40
https://xconomy.com/san-francisco/2020/01/13/allogene-springworks-to-test-drug-combo-in-multiple-myeloma-trial/60%Monthly2020-01-13 11:49
https://xconomy.com/san-diego/2020/01/11/neurocrine-in-second-epilepsy-deal-pairs-with-swiss-biotech-idorsia/60%Monthly2020-01-17 04:04
https://xconomy.com/indiana/2020/01/10/eli-lilly-gets-skin-in-the-eczema-game-with-1-1b-deal-for-dermira/60%Monthly2020-01-10 16:43
https://xconomy.com/national/2020/01/10/biotech-roundup-drug-pricing-promises-bone-disease-data-ipo-plans-more/60%Monthly2020-01-10 13:33
https://xconomy.com/boston/2020/01/10/biogen-teams-up-with-startup-camp4-to-scout-for-new-neuro-drugs/60%Monthly2020-01-10 19:42
https://xconomy.com/san-diego/2020/01/09/dtx-pharma-raises-10-6m-to-advance-new-way-to-deliver-rna-drugs/60%Monthly2020-01-10 01:32
https://xconomy.com/boston/2020/01/09/saniona-taps-former-sobi-north-america-president-rami-levin-as-new-ceo/60%Monthly2020-01-09 19:30
https://xconomy.com/san-diego/2020/01/09/ionis-adds-former-grail-chief-commercial-officer-to-executive-team/60%Monthly2020-01-09 19:49
https://xconomy.com/boston/2020/01/09/solid-bio-restructures-to-get-halted-gene-therapy-study-back-on-track/60%Monthly2020-01-09 14:56
https://xconomy.com/national/2020/01/09/uk-startups-double-in-number-backed-by-larger-scale-investments-report/60%Monthly2020-01-09 13:57
https://xconomy.com/san-diego/2020/01/09/empirico-raises-17m-inks-3-year-antisense-collaboration-with-ionis/60%Monthly2020-01-09 14:55
https://xconomy.com/san-francisco/2020/01/08/novome-lands-33m-to-tweak-a-gut-microbe-into-a-metabolic-therapy/60%Monthly2020-01-09 01:03
https://xconomy.com/san-diego/2020/01/08/mirati-adds-execs-with-commercial-experience-at-spark-bristol-myers/60%Monthly2020-01-08 12:37
https://xconomy.com/national/2020/01/07/novo-holdings-repositions-antibiotics-funding-amid-deteriorated-market/60%Monthly2020-01-08 20:40
https://xconomy.com/boston/2020/01/07/magentas-cooke-joins-ifm-therapeutics-as-chief-scientific-officer/60%Monthly2020-01-07 21:46
https://xconomy.com/san-francisco/2020/01/07/eli-lilly-veteran-enrique-conterno-named-fibrogen-ceo/60%Monthly2020-01-07 21:40
https://xconomy.com/boston/2020/01/07/apellis-rare-blood-disease-drug-tops-alexions-in-head-to-head-test/60%Monthly2020-01-07 19:10
https://xconomy.com/boston/2020/01/07/takeda-to-fund-ai-projects-at-mit-as-part-of-new-3-year-collaboration/60%Monthly2020-01-07 13:34
https://xconomy.com/san-diego/2020/01/07/celgene-seeded-pharmakea-sells-last-fibrotic-drug-candidate-to-galecto/60%Monthly2020-01-09 17:26
https://xconomy.com/boston/2020/01/07/black-diamond-lines-up-ipo-as-lead-cancer-drug-nears-clinic/60%Monthly2020-01-07 17:46
https://xconomy.com/san-diego/2020/01/07/biointervene-raises-30m-to-move-nerve-pain-drug-into-the-clinic/60%Monthly2020-01-07 18:42
https://xconomy.com/boston/2020/01/06/rhythm-pharma-ceo-gottesdeiner-to-step-down-after-fda-filing/60%Monthly2020-01-06 23:35
https://xconomy.com/san-diego/2020/01/06/biointervene-taps-charles-cohen-as-its-chief-scientific-officer/60%Monthly2020-01-06 20:21
https://xconomy.com/new-york/2020/01/06/phathom-pharma-appoints-martin-gilligan-as-chief-commercial-officer/60%Monthly2020-01-06 20:19
https://xconomy.com/new-york/2020/01/06/merck-ramps-up-kras-chase-through-licensing-deal-with-taiho-astex/60%Monthly2020-01-06 17:06
https://xconomy.com/national/2020/01/06/cf-pharmtech-raises-90m-to-advance-respiratory-drug-development/60%Monthly2020-01-06 13:39
https://xconomy.com/national/2020/01/03/bio-roundup-fda-approvals-intrexons-shift-melinta-bankruptcy-more/60%Monthly2020-01-03 19:34
https://xconomy.com/san-diego/2020/01/03/after-antitrust-challenges-illumina-and-pacbio-throw-in-towel-on-merger/60%Monthly2020-01-03 06:21
https://xconomy.com/san-francisco/2020/01/02/aridis-promotes-nazak-to-chief-financial-officer/60%Monthly2020-01-03 03:54
https://xconomy.com/boston/2020/01/02/coughlin-takes-over-as-chief-medical-officer-at-rubius/60%Monthly2020-01-03 03:56
https://xconomy.com/national/2020/01/02/no-more-fish-or-fruit-intrexon-turns-synbio-focus-to-human-health/60%Monthly2020-01-02 20:27
https://xconomy.com/national/2020/01/02/rexgenero-ceo-talks-importance-of-dialogue-in-cell-therapy-conversations/60%Monthly2020-01-02 19:54
https://xconomy.com/boulder-denver/2020/01/02/waves-huntingtons-drug-disappoints-in-clinical-trial-stock-sinks/60%Monthly2020-01-02 19:57
https://xconomy.com/national/2020/01/01/investors-go-with-gut-ahead-of-microbiome-therapy-boom-says-seventure/60%Monthly2020-01-02 18:15